Personalized Therapy - Dalcetrapib Improves Cardiovascular Outcomes 39 Percent For This Genetic Profile
Monday, January 12, 2015 - 16:50
in Health & Medicine
In a new study, an analysis of 5,749 patients who received dalcetrapib or placebo and provided DNA in a clinical study found a strong association between the effects of dalcetrapib and a specific gene called ADCY9 (adenylate cyclase 9) on chromosome 16, particularly for a specific genetic variant (rs1967309). In patients with the genetic profile AA at rs1967309, there was a 39% reduction in the composite cardiovascular endpoint with dalcetrapib compared to placebo. Supporting evidence was also obtained from a second study, which showed that patients with the favorable genetic profile also benefited from a reduction in the thickness of their carotid artery walls with dalcetrapib. read more